Advertisement

Transcatheter Mitral Valve Implantation

  • Adrian Attinger-Toller
  • Anson Cheung
  • John G. Webb
Chapter

Abstract

Mitral regurgitation (MR) is the most common cardiac valve pathology in Western countries, with an estimated prevalence of moderate and severe MR in the USA of 2–2.5 million. Though surgical valve repair and replacement are the current gold standard treatment for significant MR, surgery can be associated with significant morbidity and even mortality. This fact and the desire for less invasive approaches have led to the development of a variety of percutaneous approaches to treat MR. New transcatheter mitral repair technologies, such as the MitraClip™ system and other transcatheter devices using the concepts of annuloplasty, chordal implantation, or left ventricular (LV) remodeling, may offer a less invasive alternative to conventional surgery. However, these approaches have their own drawbacks, including failure to eliminate MR completely. Transcatheter mitral valve implantation (TMVI), in contrast, has the potential to reduce MR to a similar extent as that achieved with surgery, with the potential for reducing invasiveness and procedural risk. The first-in-human percutaneous TMVI for native mitral valve regurgitation was performed in 2012. Since then, several medical device companies have been attempting to bring suitable transcatheter valves to the market. This chapter aims to introduce the transcatheter MV implantation (TMVI) devices currently being evaluated in human trials.

Keywords

Mitral valve regurgitation Mitral valve stenosis Transcatheter mitral valve implantation Transcatheter mitral valve repair Mitral valve surgery 

References

  1. 1.
    Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation. 2001;103:1759–64.CrossRefPubMedGoogle Scholar
  3. 3.
    Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation. 2005;111:295–301.CrossRefPubMedGoogle Scholar
  4. 4.
    Lamas GA, Mitchell GF, Flaker GC, et al. Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and ventricular enlargement investigators. Circulation. 1997;96:827–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Trichon BH, Felker GM, Shaw LK, Cabell CH, O'Connor CM. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol. 2003;91:538–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med. 1996;335:1417–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Avierinos J-FF, Gersh BJ, Melton LJ, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation. 2002;106:1355–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on Valvular heart disease. Eur Heart J. 2003;24:1231–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the Management of Valvular Heart Disease (version 2012). The joint task force on the management of Valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Giornale Italiano di Cardiologia (2006). 2013;14:167–214.Google Scholar
  10. 10.
    Gillinov AM, Wierup PN, Blackstone EH, Bishay ES, Cosgrove DM, White J, Lytle BW, PM MC. Is repair preferable to replace-ment for ischemic mitral regurgitation? J Thorac Cardiovasc Surg. 2001;122:1125–41.CrossRefPubMedGoogle Scholar
  11. 11.
    Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28:1358–65.CrossRefPubMedGoogle Scholar
  12. 12.
    Alfieri O, Maisano F, De Bonis M, et al. The double-orifice technique in mitral valve repair: a simple solution for complex problems. J Thorac Cardiovasc Surg. 2001;122:674–81.CrossRefPubMedGoogle Scholar
  13. 13.
    Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (endovascular valve edge-to-edge REpair study) cohort. J Am Coll Cardiol. 2009;54:686–94.CrossRefPubMedGoogle Scholar
  14. 14.
    Tamburino C, Ussia GP, Maisano F, et al. Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting. Eur Heart J. 2010;31:1382–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chiam PT, Ruiz CE. Percutaneous transcatheter mitral valve repair: a classification of the technology. JACC Cardiovasc Interv. 2011;4:1–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Cubeddu RJ, Palacios IF. Percutaneous techniques for mitral valve disease. Cardiol Clin. 2010;28:139–53.CrossRefPubMedGoogle Scholar
  17. 17.
    Seeburger J, Rinaldi M, Nielsen SL, Salizzoni S, Lange R, Schoenburg M, Alfieri O, Borger MA, Mohr FW, Aidietis A. Off-pump transapical implantation of artificial neochordae to correct mitral regurgitation: the TACT trial (Transapical artificial chordae Tendinae) proof of concept. J Am Coll Cardiol. 2014;63:914–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Debonnaire P, Palmen M, Marsan NA, Delgado V. Contemporary imaging of normal mitral valve anatomy and function. Curr Opin Cardiol. 2012 Sep;27(5):455–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Blanke P, Naoum C, Webb J, Dvir D, Hahn RT, Grayburn P, Moss RR, Reisman M, Piazza N, Leipsic J. Multimodality imaging in the context of transcatheter mitral valve replacement: establishing consensus among modalities and disciplines. JACC Cardiovasc Imaging. 2015;8(10):1191–208.CrossRefPubMedGoogle Scholar
  20. 20.
    Ussia GP, Quadri A, Cammalleri V, De Vico P, Muscoli S, Marchei M, Ruvolo G, Sondergaard L, Romeo F. Percutaneous transfemoral-transseptal implantation of a second-generation CardiAQ™ mitral valve bioprosthesis: first procedure description and 30-day follow-up. EuroIntervention. 2016;11(10):1126–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Sondergaard L, Brooks M, Ihlemann N, Jonsson A, Holme S, Tang M, Terp K, Quadri A. Transcatheter mitral valve implantation via transapical approach: an early experience. Eur J Cardiothorac Surg. 2015;48(6):873–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Verheye S, Cheung A, Leon M, Banai S. The Tiara transcatheter mitral valve implantation system. EuroIntervention. 2015;11(Suppl W):W71–2.CrossRefPubMedGoogle Scholar
  23. 23.
    Bapat V, Lim ZY, Boix R, Pirone F. The Edwards Fortis transcatheter mitral valve implantation system. EuroIntervention. 2015;11(Suppl W):W73–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Perpetua EM, Reisman M. The Tendyne transcatheter mitral valve implantation system. EuroIntervention. 2015;11(Suppl W):W78–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Piazza N, Treede H, Moat N, Sorajja P, Popma J, Grube E, Bolling S, Adams D. The Medtronic transcatheter mitral valve implantation system. EuroIntervention. 2015;11(Suppl W):W80–1.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Adrian Attinger-Toller
    • 1
  • Anson Cheung
    • 1
  • John G. Webb
    • 1
  1. 1.Center for Heart Valve InnovationSt Paul’s HospitalVancouverCanada

Personalised recommendations